Regulatory Due Diligence for Pharmaceutical and Biologics Transactions

This practice note discusses key legal and regulatory issues to evaluate, questions to ask, and documents to review in mergers, acquisitions, investments, financings, and other transactions involving pharmaceutical or biological products.

Read now »

Related Content

• Life Sciences Due Diligence Considerations in M&A Transactions Checklist
  Identify critical due diligence considerations for life sciences M&A transactions. 

• Life Sciences FDA Matters Representation and Warranty Clause
  Use this as a starting point for an M&A representation that a target pharmaceutical company has conducted its business according to FDA, DEA, and other Medicare and Medicaid regulations.

Practical Guidance Updates
Featuring the latest updates from your Practical Guidance account.

• Listen Up! The Practical Guidance and Law360 Podcasts Resource Kit features interviews with industry-leading attorneys on cutting edge issues in the law: NFTs, Cannabis, COVID-19, and more.
• The emergence of Generative AI in Healthcare is being met with considerable concern and scrutiny because of the life-changing implications related to patient care. The new edition of the Practical Guidance Journal features an in-depth look at cautions and legal considerations.
• Legal Developments provide the latest updates and analyses of emerging topics impacting your practice area. Visit the Legal Developments page to see the latest topics, which also include breaking legal news and related Practical Guidance content. 

PRACTICAL GUIDANCE CUSTOMER EMAIL EDITION ON THE WEB

Experience results today with practical guidance, legal research, and data-driven insights—all in one place.

Experience Lexis+